Basiliximab
Simulect (basiliximab) is an antibody pharmaceutical. Basiliximab was first approved as Simulect on 1998-05-12. It has been approved in Europe to treat graft rejection and kidney transplantation. It is known to target interleukin-2 receptor subunit alpha.
| Trade Name | Simulect |
|---|---|
| Common Name | Basiliximab |
| Indication | graft rejection, kidney transplantation |
| Drug Class | Monoclonal antibodies: chimeric, immunomodulating |
